{"entity":{"id":"panther-therapeutics","kind":"company","name":"PanTher Therapeutics","aka":[],"tldr":"PanTher Therapeutics makes absorbable patches that release chemotherapy directly at the tumour over a long period. Its first product, PTM-101, which contains paclitaxel, is in an early trial alongside standard treatment before surgery for pancreatic cancer.","summary":"PanTher Therapeutics, Inc., with offices in Austin, Texas, and Watertown, Massachusetts, develops long-lasting, high-dose local chemotherapy products on its Sagittari platform, designed to deliver drug continuously at the tumour site. Its lead, PTM-101, is described in the registry as an absorbable drug product containing paclitaxel, tested as an adjunct to neoadjuvant therapy in treatment-naive borderline resectable and locally advanced pancreatic ductal adenocarcinoma in a phase 1b study (NCT06673017) with US and Australian sites; the company reported completing its first cohort in September 2025 and dose escalation in May 2026. The company lists a USD 1.8 million supplemental award from the Cancer Prevention and Research Institute of Texas in May 2026. Its first registered cancer trial, NCT06673017, was posted on ClinicalTrials.gov in November 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://panthertx.com/"},{"label":"Company news","url":"https://panthertx.com/news"},{"label":"ClinicalTrials.gov: phase 1b trial of PTM-101 (NCT06673017)","url":"https://clinicaltrials.gov/study/NCT06673017"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and venture financing not stated on the company website.","The USD 1.8 million CPRIT figure is from the company's news list; the CPRIT page returned HTTP 403 and the Business Wire releases returned 403 on 29 October 2026, so no funding row is recorded.","The website lists Austin and Watertown without naming a headquarters; Austin is used."],"hq":"Austin, TX","country":"US","companyType":"biotech","website":"https://panthertx.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/panther-therapeutics/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}]}}